An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Researchers reported that an experimental antibody drug called IBIO-610 changed how weight loss happened when given with semaglutide in obese nonhuman primates. In short, monkeys treated with both drugs lost more fat and less lean mass (muscle and other nonfat tissue) than those given semaglutide alone. This is an early animal study, not a human trial, so it’s a preliminary result rather than a ready-to-use treatment. IBIO-610 targets a protein called Activin E. Activin E is part of a family of signaling molecules our bodies use to control things like metabolism and tissue growth. An “antibody” here is a lab-made molecule that binds to Activin E and blocks its activity. Semaglutide, which many people know by brand names like Ozempic or Wegovy, is a drug that mimics a gut hormone to reduce appetite and slow stomach emptying. The idea tested here is that blocking Activin E while using semaglutide might steer weight loss toward fat rather than muscle. What the study actually shows is limited but interesting. In obese primates, adding IBIO-610 to semaglutide led to a greater proportion of the lost weight coming from fat tissue instead of lean tissue. The report does not mean the total weight lost was dramatically larger — it’s about composition of loss. Also, these results are in nonhuman primates, which are biologically closer to humans than rodents but still not people. We don’t have human safety or effectiveness data yet, and the size and details of the primate study (how many animals, exact percentages, length of treatment) weren’t given in the short snippet. Why this could matter: when people lose weight, preserving muscle and other lean tissue is important for strength, metabolism, and long-term health. Semaglutide and similar drugs are effective at reducing body weight, but some of that loss can include lean mass. A therapy that shifts loss toward fat could improve functional outcomes and possibly help maintain metabolic rate. If human trials eventually show the same effect, it could be an add-on for people using GLP-1 drugs who want to protect muscle while losing fat. There are important caveats and risks. Blocking a signaling protein like Activin E might have unintended effects — that family of proteins influences many tissues, and long-term safety is unknown. Animal results don’t always translate to humans. We also don’t know dosing, side effects, or whether IBIO-610 changes appetite, energy levels, or other organs. Until rigorous human trials are done and regulators review the data, this is an experimental approach, not a treatment option. People should not seek unapproved versions or presume it’s safe. Bottom line: In obese primates, Bio’s IBIO-610 antibody appeared to make semaglutide-induced weight loss come more from fat than from muscle, which is promising but preliminary and unproven in humans.
Source: BioPharm International